ClinicalTrials.gg
RecruitingNCT07275905Updated Oct 8, 2026

Bacteriophages for Adults With Cystic Fibrosis and Chronic Achromobacter Lung Infection

A Phase 1 interventional study of AchromoPhage in Cystic Fibrosis (CF) and Achromobacter Infection, sponsored by Ghady Haidar. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Ghady Haidar · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Oct 8, 2026Start date movedEligibility revised+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 717 studies in Cystic Fibrosis with a site in United States — 85 open to participants now, 111 under way, 8 of them phase 3. Cystic Fibrosis · United States.

Planned enrollment
433rd of 517
12 · median 36
Started
2026
with 15 others
Phase 1
77 of 717
8 open now
Primary completion
2028-01
later than 77 of 108 live
Registered
702nd of 717
by date

Among the 717 studies in Cystic Fibrosis with a site in United States, this one is the 433rd largest by planned enrollment of the 517 interventional ones that give a count, is one of 16 that started in 2026, is one of 77 in phase 1, reaches primary completion later than 77 of the 108 other live ones, and was the 702nd registered.

Cystic Fibrosis

1,622 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

85 of the 717 studies in Cystic Fibrosis with a site in United States are open now. Recruiting first, the newest first:

79 more — sign in →

All 85 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 87 take children under 18; 42 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 717 studies in Cystic Fibrosis with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if a new treatment called AchromoPhage is safe and well tolerated in adults with cystic fibrosis (CF) who have long-term lung infections caused by Achromobacter bacteria. AchromoPhage is a mixture of four naturally occurring viruses, called phages, that are designed to target and kill Achromobacter.

This study will include 12 participants. People will be randomly assigned to one of three groups to receive AchromoPhage in different ways: by inhalation only, by intravenous (IV) infusion only, or by inhalation followed by IV infusion.

Participants will:

  • Receive the study drug during clinic visits over a period of three weeks.
  • Provide blood, sputum, nasal, and oral samples so researchers can measure how the phages move through the body, how long they stay, and whether the body develops a response against them.
  • Complete breathing tests and quality-of-life questionnaires.

The main question this study will answer is whether AchromoPhage causes any serious or treatment-limiting side effects in the first 42 days after dosing. Researchers will also look at changes in lung function, quality of life, phage levels in the body, and how the treatment affects Achromobacter and other bacteria in the lungs.

The study is being run at the University of Pittsburgh (Pittsburgh, PA).

Read the detailed description

AchromoPhage is a naturally derived bacteriophage cocktail composed of four genetically distinct, obligately lytic phages (phiACH01, phiACH04, phiACH06, and phiACH07) with demonstrated in vitro activity against Achromobacter species. The cocktail showed activity against more than 75% of a panel of 17 genetically diverse Achromobacter isolates collected from adults with cystic fibrosis. This study is designed to evaluate the safety and tolerability of AchromoPhage in adults with cystic fibrosis who have chronic Achromobacter lung infection.

This is an open-label, randomized Phase 1 pilot and feasibility trial conducted at the University of Pittsburgh.. Eligible participants will be randomized to receive AchromoPhage by one of three delivery routes: inhaled administration, intravenous administration, or sequential inhaled followed by intravenous administration in the same visit. Each participant will receive three weekly administrations with escalating doses.

In addition to evaluating safety and tolerability, the trial will assess lung function and health-related quality of life, characterize pharmacokinetic profiles of AchromoPhage in blood and airway samples, and evaluate the humoral immune response to the administered phages. Exploratory analyses will examine pharmacodynamic effects, including changes in Achromobacter abundance, bacterial community profiles, antibiotic-phage interactions, and phage-pathogen dynamics.

03

Conditions studied

  • Cystic Fibrosis (CF)
  • Achromobacter Infection

Browse trials for

Keywords

  • Bacteriophage Therapy
  • Phage Therapy
  • AchromoPhage
  • Multidrug-Resistant Infections
  • Lung Infection
  • Pulmonary Infection
  • cystic fibrosis
  • Achromobacter
04

Who can participate

The criteria were revised on the registry on Oct 8, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • In order to be eligible to participate in this study, an individual must meet all of the following criteria:

    1. Adults of any gender, age 18 years or greater at the time of enrollment.
    2. Weight of 40 kg or greater.
    3. Diagnosed with cystic fibrosis (CF), including transplant recipients
    4. Stable respiratory symptoms within 30 days prior to screening, with no change in CF maintenance medications (including cystic fibrosis transmembrane conductance regulator (CFTR) modulators) within 30 days prior to screening.
    5. Chronic Achromobacter respiratory infection, defined as isolation by culture of Achromobacter species from two or more respiratory, oral, and/or nasopharyngeal samples provided by the participant within 24 months before the date of pre-screening. Polymicrobial infection (co-isolation of other organisms) does not exclude participation.
    6. At least one Achromobacter isolate cultured from a respiratory, oral, and/or nasopharyngeal sample within 12 months of the date of planned enrollment must be susceptible to at least 1 phage in AchromoPhage cocktail using study assays.
    7. ≥ (greater than or equal to) 40% of predicted at time of screening
    8. Ability and willingness to provide or, if applicable, the ability and willingness of legal guardian/representative to provide informed consent.
    9. Willingness to comply with study procedures.
    10. Ability to travel to the University of Pittsburgh or the University of California San Diego if activated for in-person phage administration visits.
    11. Agreement not to enroll in other bacteriophage studies or receive bacteriophages for clinical care during the study, except in life-saving situations.
    12. For females of , a negative urine pregnancy test at the time of consent (before randomization and dosing).
    13. Willingness to use highly effective or other preventive measures to avoid conception during the study and for 6 months after the last phage dose.

Note, criteria 5 and 6 are the microbiologic criteria.

Exclusion criteria

Exclusion Criteria:

  • An individual who meets any of the following criteria will be excluded from participation in this study:

    1. Serious medical illness requiring systemic treatment or hospitalization within 30 days prior to screening (unless medically stable and approved by the investigator).
    2. Acute pulmonary exacerbation requiring systemic antibiotics within 30 days prior to screening.
    3. Acute respiratory illness, including viral infection, within 30 days prior to screening.
    4. Grade 3 or higher (ALT) or aspartate aminotransferase (AST) at or within 30 days prior to screening, defined as ALT or AST values >5.0 x (ULN).
    5. Currently breastfeeding, pregnant, or planning to become pregnant within 6 months.
    6. \< 8 g/dL
    7. \< 1000 cells/uL
    8. Intolerance to inhaled therapies.
    9. Known allergy or sensitivity to components of the AchromoPhage cocktail.
    10. Any other condition that, in the investigator's opinion, would interfere with the conduct of the study or would not be in the participant's best interest.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Inhaled Alone Arm

    Participants will receive a single weekly administration of AchromoPhage via the inhaled route for a total of three administrations. Each weekly administration consists of escalating inhaled doses of the cocktail: * Day 0 (visit 1, 1st week): 4×10⁷ total PFU * Day 7 (visit 2, 2nd week): 4×10⁸ total PFU * Day 14 (visit 3, 3rd week): 4×10⁹ total PFU

    Biological: AchromoPhage

  • Experimental
    Intravenous Alone Arm

    Participants will receive a single weekly administration of AchromoPhage via the intravenous route. Each weekly administration consists of escalating intravenous doses of the cocktail. * Day 0 (visit 1, 1st week): 4×10⁷ total PFU * Day 7 (visit 2, 2nd week): 4×10⁸ total PFU * Day 14 (visit 3, 3rd week): 4×10⁹ total PFU

    Biological: AchromoPhage

  • Experimental
    Combination Inhaled + Intravenous Arm

    Participants will receive a single weekly administration of AchromoPhage, which will consist of an inhaled dose followed by an intravenous dose given during the same study visit, with a 60-minute wait between doses. Weekly dose escalation will apply to each route, resulting in a total dose that is double that of the single route arms, as follows: * Day 0 (visit 1, 1st week): 8×10⁷ totalPFU \[i.e. 4×10⁷ total PFU inhaled, followed by a 60-minute wait, then 4×10⁷ total PFU intravenous\] * Day 7 (visit 2, 2nd week):8×10⁸ total PFU \[i.e. 4×10⁸ total PFU inhaled, followed by a 60-minute wait, then 4×10⁸ total PFU intravenous\] * Day 14 (visit 3, 3rd week): 8×10⁹ total PFU \[i.e. 4×10⁹ total PFU inhaled, followed by a 60-minute wait, then 4×10⁹ total PFU intravenous\]

    Biological: AchromoPhage

Interventions

  • BiologicalAchromoPhage

    AchromoPhage is a cocktail of four genetically distinct, obligately lytic bacteriophages (phiACH01, phiACH04, phiACH06, phiACH07) with in vitro activity against \>75% of a panel of 17 genetically diverse Achromobacter isolates from persons with cystic fibrosis. In this study, AchromoPhage will be administered by inhaled, intravenous, or sequential inhaled + intravenous routes with weekly dose escalation. Each participant will receive three weekly administrations, with escalating total doses of 4×10⁷ PFU, 4×10⁸ PFU, and 4×10⁹ PFU per route (double the total dose in the combination arm).

    Also known as: Phage, Bacteriophage

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-related Grade ≥4 adverse events or treatment-limiting toxicities

    Incidence of treatment-related Grade 4 or higher adverse events or any treatment-limiting toxicities, assessed overall and by treatment group, from the first dose through Day 42. Severity grading will follow the protocol-specified adverse event definitions.

    Time frame: 42 Days

Secondary outcomes

  1. Change in health-related quality of life measured by the Cystic Fibrosis Questionnaire-(CFQ-R)

    Change in health-related quality of life from baseline to Day 42 measured using the Cystic Fibrosis Questionnaire-(CFQ-R), a validated, disease-specific instrument assessing physical, emotional, social, and respiratory health domains in cystic fibrosis. Construct measured: Health-related quality of life. Score range: Each domain generates a score from 0 to 100, where higher scores indicate better quality of life. Scoring: Domain scores are computed as linear transformations of raw responses; domains are not summed into a single composite score. Interpretation: Increases in domain scores represent improvement.

    Time frame: 42 Days

  2. AchromoPhage Concentration by qPCR (Pharmacokinetic Outcome Measure)

    Quantitative serum concentrations of each phage component of AchromoPhage will be measured by qPCR using primers that will amplify each of the 4 phages in the cocktail at predefined time points, following inhaled, intravenous, or combined administration. Blood PCR: Collected at 0-, 10-, 30-, 60-, 120-, 180-, and 240-minute intervals following AchromoPhage administration during dosing visits (Days 0, 7, and 14) and once on Days 21 and 42. Sputum, nasal swabs, and oral swabs: Collected weekly (Days 0, 7, 14, 21, 28, 35, and 42).

    Time frame: Blood: Days 0, 7, 14, 21, 42. Sputum, nasal swabs, and oral swabs: Days 0, 7, 14, 21, 28, 35, and 42.

  3. Number of Participants With Treatment-Emergent Serum Phage-Neutralizing Antibody Activity

    Quantitative phage-neutralizing antibody activity will be measured in serum samples to assess treatment-emergent humoral immune responses following AchromoPhage administration.

    Time frame: Days 0, 7, 14, 21, 28, and 42

07

Study locations

1 of 1 sites recruiting
  • University of Pittsburgh
    Pittsburgh, Pennsylvania 15213, United States
    Recruiting
    • Sarah Barrett - Sr. Clinical Research Coordinator, MPH · Contactsnookse@upmc.edu · 412-648-6377
    • Daria Van Tyne, PhD · Principal investigator
    • Ghady Haidar, MD · Principal investigator
08

References and documents

Publications

  • Stellfox ME, Fernandes C, Shields RK, Haidar G, Hughes Kramer K, Dembinski E, Mangalea MR, Arya G, Canfield GS, Duerkop BA, Van Tyne D. Bacteriophage and antibiotic combination therapy for recurrent Enterococcus faecium bacteremia. mBio. 2024 Mar 13;15(3):e0339623. doi: 10.1128/mbio.03396-23. Epub 2024 Feb 14. PubMed 38353560 ↗
  • Haidar G, Chan BK, Cho ST, Hughes Kramer K, Nordstrom HR, Wallace NR, Stellfox ME, Holland M, Kline EG, Kozar JM, Kilaru SD, Pilewski JM, LiPuma JJ, Cooper VS, Shields RK, Van Tyne D. Phage therapy in a lung transplant recipient with cystic fibrosis infected with multidrug-resistant Burkholderia multivorans. Transpl Infect Dis. 2023 Apr;25(2):e14041. doi: 10.1111/tid.14041. Epub 2023 Mar 2. PubMed 36864824 ↗
  • Suh GA, Lodise TP, Tamma PD, Knisely JM, Alexander J, Aslam S, Barton KD, Bizzell E, Totten KMC, Campbell JL, Chan BK, Cunningham SA, Goodman KE, Greenwood-Quaintance KE, Harris AD, Hesse S, Maresso A, Nussenblatt V, Pride D, Rybak MJ, Sund Z, van Duin D, Van Tyne D, Patel R; Antibacterial Resistance Leadership Group. Considerations for the Use of Phage Therapy in Clinical Practice. Antimicrob Agents Chemother. 2022 Mar 15;66(3):e0207121. doi: 10.1128/AAC.02071-21. Epub 2022 Jan 18. PubMed 35041506 ↗
  • Schooley RT, Biswas B, Gill JJ, Hernandez-Morales A, Lancaster J, Lessor L, Barr JJ, Reed SL, Rohwer F, Benler S, Segall AM, Taplitz R, Smith DM, Kerr K, Kumaraswamy M, Nizet V, Lin L, McCauley MD, Strathdee SA, Benson CA, Pope RK, Leroux BM, Picel AC, Mateczun AJ, Cilwa KE, Regeimbal JM, Estrella LA, Wolfe DM, Henry MS, Quinones J, Salka S, Bishop-Lilly KA, Young R, Hamilton T. Development and Use of Personalized Bacteriophage-Based Therapeutic Cocktails To Treat a Patient with a Disseminated Resistant Acinetobacter baumannii Infection. Antimicrob Agents Chemother. 2017 Sep 22;61(10):e00954-17. doi: 10.1128/AAC.00954-17. Print 2017 Oct. PubMed 28807909 ↗
  • Tamma PD, Souli M, Billard M, Campbell J, Conrad D, Ellison DW, Evans B, Evans SR, Greenwood-Quaintance KE, Filippov AA, Geres HS, Hamasaki T, Komarow L, Nikolich MP, Lodise TP, Nayak SU, Norice-Tra C, Patel R, Pride D, Russell J, Van Tyne D, Chambers HF, FowlerJr VG, Schooley RT; Antibacterial Resistance Leadership Group. Safety and microbiological activity of phage therapy in persons with cystic fibrosis colonized with Pseudomonas aeruginosa: study protocol for a phase 1b/2, multicenter, randomized, double-blind, placebo-controlled trial. Trials. 2022 Dec 28;23(1):1057. doi: 10.1186/s13063-022-07047-5. PubMed 36578069 ↗
  • De Baets F, Schelstraete P, Van Daele S, Haerynck F, Vaneechoutte M. Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance. J Cyst Fibros. 2007 Jan;6(1):75-8. doi: 10.1016/j.jcf.2006.05.011. Epub 2006 Jun 21. PubMed 16793350 ↗
  • Tetart M, Wallet F, Kyheng M, Leroy S, Perez T, Le Rouzic O, Wallaert B, Prevotat A. Impact of Achromobacter xylosoxidans isolation on the respiratory function of adult patients with cystic fibrosis. ERJ Open Res. 2019 Dec 8;5(4):00051-2019. doi: 10.1183/23120541.00051-2019. eCollection 2019 Oct. PubMed 31832429 ↗
  • Uyttebroek S, Chen B, Onsea J, Ruythooren F, Debaveye Y, Devolder D, Spriet I, Depypere M, Wagemans J, Lavigne R, Pirnay JP, Merabishvili M, De Munter P, Peetermans WE, Dupont L, Van Gerven L, Metsemakers WJ. Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review. Lancet Infect Dis. 2022 Aug;22(8):e208-e220. doi: 10.1016/S1473-3099(21)00612-5. Epub 2022 Mar 3. PubMed 35248167 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Jan 2028, 17 months after the start.

Of 62 phase 1 interventional studies under Cystic Fibrosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 34. This study's planned 17 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2025
First posted
Dec 10, 2025
StartActual
Aug 20, 2026
Primary completionEst.
Jan 2028
CompletionEst.
Feb 2028
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site removed
Show 1 removed
  • University of California San Diego (UCSD) · San Diego, United States
Oct 8, 2026
Start date
Aug 1, 2026→Aug 20, 2026 (actual)
Oct 8, 2026
Eligibility
5 inclusion criteria edited; 2 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedDiagnosed with cystic fibrosis (CF)., including transplant recipients
  • ChangedBefore Stable respiratory symptoms within 30 days prior to screening.Now Stable respiratory symptoms within 30 days prior to screening, with no change in CF maintenance medications (including cystic fibrosis transmembrane conductance regulator (CFTR) modulators) within 30 days prior to screening.
  • EditedChronic Achromobacter respiratory infection, defined as isolation by culture of Achromobacter species from two or more respiratory, oral, and/or nasopharyngeal samples provided by the participant within 24 months before the date of pre-screening. Polymicrobial infection (co-isolation of other organisms) does not exclude participation.
  • EditedAt least one Achromobacter isolate cultured from a respiratory, oral, and/or nasopharyngeal sample provided by the participant no more than 60 days beforewithin 12 months of the date of planned enrollment must be susceptible to at least 1 phage in AchromoPhage cocktail using study assays.
  • EditedAbility to travel to the University of Pittsburgh or the University of California San Diego if activated for in-person phage administration and in-person visits.
Exclusion criteria
  • EditedSerious medical illness requiring systemic treatment or hospitalization within 30 days prior to screening (unless medically stable and approved by the PIinvestigator).
  • EditedAny other condition that, in the PIinvestigator's opinion, would interfere with the conduct of the study or would not be in the participant's best interest.
Oct 8, 2026
Contact
Study contact changed: B•••@pitt.edu · •••6380→s•••@upmc.edu · •••6377. See the current contact
Oct 8, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • University of Pittsburgh · Pittsburgh, United StatesContact b•••@pitt.edu · •••6380→s•••@upmc.edu · •••6377Contact person changed (no phone or email listed)Contact added (no phone or email listed)
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    1 site removed
    Show 1 removed
    • University of California San Diego (UCSD) · San Diego, United States
    Start date Aug 1, 2026→Aug 20, 2026 (now actual)
    Eligibility 5 inclusion criteria edited; 2 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedDiagnosed with cystic fibrosis (CF)., including transplant recipients
    • ChangedBefore Stable respiratory symptoms within 30 days prior to screening.Now Stable respiratory symptoms within 30 days prior to screening, with no change in CF maintenance medications (including cystic fibrosis transmembrane conductance regulator (CFTR) modulators) within 30 days prior to screening.
    • EditedChronic Achromobacter respiratory infection, defined as isolation by culture of Achromobacter species from two or more respiratory, oral, and/or nasopharyngeal samples provided by the participant within 24 months before the date of pre-screening. Polymicrobial infection (co-isolation of other organisms) does not exclude participation.
    • EditedAt least one Achromobacter isolate cultured from a respiratory, oral, and/or nasopharyngeal sample provided by the participant no more than 60 days beforewithin 12 months of the date of planned enrollment must be susceptible to at least 1 phage in AchromoPhage cocktail using study assays.
    • EditedAbility to travel to the University of Pittsburgh or the University of California San Diego if activated for in-person phage administration and in-person visits.
    Exclusion criteria
    • EditedSerious medical illness requiring systemic treatment or hospitalization within 30 days prior to screening (unless medically stable and approved by the PIinvestigator).
    • EditedAny other condition that, in the PIinvestigator's opinion, would interfere with the conduct of the study or would not be in the participant's best interest.
    Contact Study contact changed: B•••@pitt.edu · •••6380→s•••@upmc.edu · •••6377. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • University of Pittsburgh · Pittsburgh, United StatesContact b•••@pitt.edu · •••6380→s•••@upmc.edu · •••6377Contact person changed (no phone or email listed)Contact added (no phone or email listed)
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07275905
Lead sponsor
Ghady Haidar
Collaborators
Cystic Fibrosis Foundation
Responsible party
Ghady Haidar (Associate Professor of Medicine; Co-chair, Pittsburgh Phage Program (P3), University of Pittsburgh) — Sponsor-investigator
First posted
Dec 10, 2025
Start date
Aug 20, 2026
Primary completion
Jan 2028 (estimated)
Completion
Feb 2028 (estimated)
Last update
Oct 8, 2026

Study contacts

Sarah Barrett - Sr. Clinical Research Coordinator, MPH
Contact
snookse@upmc.edu
412-648-6377
Kailey Hughes Kramer - Director, Translational Research Unit, PhD MPH
Contact
hugheskl4@upmc.edu
412-648-6453
Ghady Haidar, MD
principal investigator · University of Pittsburgh

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion